| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 1/10-1/50 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Glutamate carboxypeptidase 2, Cell growth-inhibiting gene 27 protein, Folate hydrolase 1, Folylpoly-gamma-glutamate carboxypeptidase, FGCP, Glutamate carboxypeptidase II, GCPII, Membrane glutamate carboxypeptidase, mGCP, N-acetylated-alpha-linked acidic dipeptidase I, NAALADase I, Prostate-specific membrane antigen, PSM, PSMA, Pteroylpoly-gamma-glutamate carboxypeptidase, FOLH1, FOLH, NAALAD1, PSM, PSMA |
| Entrez GeneID | 2346 |
| WB Predicted band size | 84.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This FOLH1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 161-190 amino acids from the N-terminal region of human FOLH1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与FOLH1(N端)抗体相关的参考文献概览：
1. **《Prostate-specific membrane antigen (PSMA) in benign prostate hyperplasia and prostate cancer》**
- 作者：Heston WD et al.
- 摘要：研究FOLH1/PSMA蛋白在前列腺增生和癌变中的表达差异，使用N端特异性抗体验证其膜定位，并探讨其作为诊断标志物的潜力。
2. **《Characterization of a novel anti-PSMA antibody for targeting prostate cancer》**
- 作者：Chang SS et al.
- 摘要：开发并验证了一种针对PSMA蛋白N端表位的单克隆抗体，证明其在体外和动物模型中可特异性识别前列腺癌细胞，为靶向治疗提供工具。
3. **《FOLH1 antibodies in the detection of metastatic prostate cancer lesions》**
- 作者：Afshar-Oromieh A et al.
- 摘要：评估基于N端抗体的FOLH1免疫PET显像技术，证明其在转移性前列腺癌病灶检测中的高灵敏度和特异性，优于传统影像学方法。
注：部分文献可能需要通过PubMed或Google Scholar进一步检索DOI获取全文。若需特定抗体货号的引用文献，建议参考供应商(如CST、Abcam)产品页面的引用论文列表。
The FOLH1 (N-term) antibody targets the N-terminal region of folate hydrolase 1 (FOLH1), also known as prostate-specific membrane antigen (PSMA) or glutamate carboxypeptidase II (GCPII). FOLH1 is a type II transmembrane glycoprotein with enzymatic activity, primarily cleaving terminal glutamate residues from substrates like N-acetylaspartylglutamate (NAAG) and poly-γ-glutamated folate. It plays roles in nutrient absorption, folate metabolism, and neuropeptide regulation.
FOLH1 is highly expressed in prostate cancer cells and is a well-established biomarker for prostate cancer diagnosis, prognosis, and therapeutic targeting. It is also found in tumor neovasculature of various cancers (e.g., renal, colorectal), making it a candidate for antibody-based imaging or therapy. The N-terminal region is extracellular, enabling antibodies against this domain to bind cell-surface FOLH1. facilitating applications in immunohistochemistry (IHC), flow cytometry, or functional studies.
The FOLH1 (N-term) antibody is widely used in research to investigate FOLH1’s biological roles, tumor expression patterns, and therapeutic potential. Its specificity for the N-terminus ensures recognition of full-length, membrane-bound FOLH1. avoiding cross-reactivity with truncated isoforms. This antibody supports advancements in developing PSMA-targeted therapies, including antibody-drug conjugates, radioligands, and CAR-T cell platforms, underscoring its importance in oncology and molecular biology research.
×
